What is the role of high-dose chemotherapy in the era of targeted therapies?

被引：15

作者：

Hortobagyi, GN ^{[1
]}

机构：

[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 12期

关键词：

D O I：

10.1200/JCO.2004.02.927

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：2263 / 2266

页数：4

共 30 条

[1]

Abe O, 1998, LANCET, V352, P930

[2]

[Anonymous], P AM SOC CLIN ONCOL

[3]

ARIEL I M, 1975, Journal of Surgical Oncology, V7, P331, DOI 10.1002/jso.2930070502

[4]

Baum M, 2002, LANCET, V359, P2131

[5] Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer:: a randomised trial [J].

Bergh, J ;

Wiklund, T ;

Erikstein, B ;

Lidbrink, E ;

Lindman, H ;

Malmström, P ;

Kellokumpu-Lehtinen, P ;

Bengtsson, NO ;

Söderlund, G ;

Anker, G ;

Wist, E ;

Ottosson, S ;

Salminen, E ;

Ljungman, P ;

Holte, H ;

Nilsson, J ;

Blomqvist, C ;

Wilking, N .

LANCET, 2000, 356 (9239) :1384-1391

[6] DOSE-RESPONSE EFFECT OF ADJUVANT CHEMOTHERAPY IN BREAST-CANCER [J].

BONADONNA, G ;

VALAGUSSA, P .

NEW ENGLAND JOURNAL OF MEDICINE, 1981, 304 (01) :10-15

[7]

BUZDAR AU, 1984, RECENT RES CANCER, V96, P141

[8] Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of intergroup trial C9741/cancer and leukemia group B trial 9741 [J].

Citron, ML ;

Berry, DA ;

Cirrincione, C ;

Hudis, C ;

Winer, EP ;

Gradishar, WJ ;

Davidson, NE ;

Martino, S ;

Livingston, R ;

Ingle, JN ;

Perez, EA ;

Carpenter, J ;

Hurd, D ;

Holland, JF ;

Smith, BL ;

Sartor, CI ;

Leung, EH ;

Abrams, J ;

Schilsky, RL ;

Muss, HB ;

Norton, L .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (08) :1431-1439

[9]

CROWN JP, 2002, P AN M AM SOC CLIN, V21, pA42

[10] Outcome of extensive Evaluation before adjuvant therapy in women with breast cancer and 10 or more positive axillary lymph nodes [J].

Crump, M ;

Goss, PE ;

Prince, M ;

Girouard, C .

JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (01) :66-69

← 1 2 3 →